Paper28813655
Making It Personal: Neoantigen Vaccines in Metastatic Melanoma.
Hellmann MD and 1 other. Immunity, 2017. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. Making It Personal: Neoantigen Vaccines in Metastatic Melanoma. Papers, record 28813655. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28813655
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, Neoplasm | Major topic |
| Cancer Vaccines | Major topic |
| Immunotherapy | Major topic |
| Melanoma | Major topic |
| Skin Neoplasms | Major topic |
| Animals | |
| Autoantigens | |
| Clinical Trials, Phase I as Topic | |
| Humans | |
| Mutation | |
| Neoplasm Metastasis | |
| Vaccines, Subunit |
Source PubMed
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment on | 28678778 | An immunogenic personal neoantigen vaccine for patients with melanoma. | https://conductscience.org/library/papers/28678778 | PubMed |
| Comment on | 28678784 | Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. | https://conductscience.org/library/papers/28678784 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40129944 | TCR-T cell therapy for solid tumors: challenges and emerging solutions. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40129944 | PubMed |
| 39872522 | DNA vaccines as promising immuno-therapeutics against cancer: a new insight. | Front Immunol | 2024 | https://conductscience.org/library/papers/39872522 | PubMed |
| 38713894 | Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma. | Blood Adv | 2024 | https://conductscience.org/library/papers/38713894 | PubMed |
| 38625508 | Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy. | Mol Biotechnol | 2025 | https://conductscience.org/library/papers/38625508 | PubMed |
| 37554274 | Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma. | Theranostics | 2023 | https://conductscience.org/library/papers/37554274 | PubMed |
| 37294501 | The future of cancer immunotherapy: DNA vaccines leading the way. | Med Oncol | 2023 | https://conductscience.org/library/papers/37294501 | PubMed |
| 35126730 | Neoantigens and their potential applications in tumor immunotherapy. | Oncol Lett | 2022 | https://conductscience.org/library/papers/35126730 | PubMed |
| 35036074 | Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma. | Oncoimmunology | 2022 | https://conductscience.org/library/papers/35036074 | PubMed |
| 34703645 | Farnesylthiosalicylic acid-derivatized PEI-based nanocomplex for improved tumor vaccination. | Mol Ther Nucleic Acids | 2021 | https://conductscience.org/library/papers/34703645 | PubMed |
| 32483434 | Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. | Theranostics | 2020 | https://conductscience.org/library/papers/32483434 | PubMed |
| 32322001 | The premise of personalized immunotherapy for cancer dormancy. | Oncogene | 2020 | https://conductscience.org/library/papers/32322001 | PubMed |
| 32295135 | Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer. | Vaccines (Basel) | 2020 | https://conductscience.org/library/papers/32295135 | PubMed |
| 31979205 | Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update. | Pharmaceutics | 2020 | https://conductscience.org/library/papers/31979205 | PubMed |
| 31134073 | Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. | Front Immunol | 2019 | https://conductscience.org/library/papers/31134073 | PubMed |
| 31040852 | Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity. | Front Immunol | 2019 | https://conductscience.org/library/papers/31040852 | PubMed |
| 30953535 | Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. | J Exp Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30953535 | PubMed |
| 30923036 | Immunotherapy of Melanoma: Facts and Hopes. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30923036 | PubMed |
| 30218648 | Stochastic modeling of tumor progression and immune evasion. | J Theor Biol | 2018 | https://conductscience.org/library/papers/30218648 | PubMed |
| 30013560 | Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy. | Front Immunol | 2018 | https://conductscience.org/library/papers/30013560 | PubMed |
| 29209575 | Trial watch: DNA-based vaccines for oncological indications. | Oncoimmunology | 2017 | https://conductscience.org/library/papers/29209575 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28813655
GET https://conductscience.org/api/papers/v1/28813655/authors